 NPS Pharmaceuticals is an emerging development powerhouse that effectively brings biopharmaceuticals to patients with unmet medical needs. The company's lead clinical programs currently in development are innovative therapies for patients with rare gastrointestinal and endocrine disorders. NPS has two late-stage development programs. A New Drug Application has been accepted and filed for review by the U.S. Food and Drug Administration for GATTEX as a treatment for adult short bowel syndrome and a Phase 3 study has been completed for NATPARATM (recombinant human parathyroid hormone (rhPTH (1-84)) in hypoparathyroidism. NPS complements its internal clinical programs with a valuable royalty-generating portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil. |
"A transformational period is ahead where NPS will evolve from a development company into a commercial-stage organization, and I am confident that we have the talent to achieve this objective."
Francois Nader, MD
President and Chief Executive Officer
